These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36671465)

  • 1. The Anti-Cancer Activity of Pentamidine and Its Derivatives (WLC-4059) Is through Blocking the Interaction between S100A1 and RAGE V Domain.
    Parveen N; Chiu WJ; Shen LC; Chou RH; Sun CM; Yu C
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain.
    Khan MI; Su YK; Zou J; Yang LW; Chou RH; Yu C
    PLoS One; 2018; 13(2):e0190545. PubMed ID: 29444082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentamidine blocks the interaction between mutant S100A5 and RAGE V domain and inhibits the RAGE signaling pathway.
    Cho CC; Chou RH; Yu C
    Biochem Biophys Res Commun; 2016 Aug; 477(2):188-94. PubMed ID: 27297108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.
    Huang YK; Chou RH; Yu C
    J Biol Chem; 2016 Jul; 291(27):14300-14310. PubMed ID: 27226584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A4 inhibits cell proliferation by interfering with the S100A1-RAGE V domain.
    Khan MI; Yuan T; Chou RH; Yu C
    PLoS One; 2019; 14(2):e0212299. PubMed ID: 30779808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking the interaction between S100A9 and RAGE V domain using CHAPS molecule: A novel route to drug development against cell proliferation.
    Chang CC; Khan I; Tsai KL; Li H; Yang LW; Chou RH; Yu C
    Biochim Biophys Acta; 2016 Nov; 1864(11):1558-69. PubMed ID: 27524699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into calcium-bound S100P and the V domain of the RAGE complex.
    Penumutchu SR; Chou RH; Yu C
    PLoS One; 2014; 9(8):e103947. PubMed ID: 25084534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking the interface region amongst S100A6 and RAGE V domain via S100B protein.
    Sung HY; Dowarha D; Chou RH; Yu C
    Biochem Biophys Res Commun; 2020 Dec; 533(3):332-337. PubMed ID: 32958253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the interaction between S100A9 protein and RAGE V domain using S100A12 protein.
    Katte R; Yu C
    PLoS One; 2018; 13(6):e0198767. PubMed ID: 29902210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking the Interactions between Calcium-Bound S100A12 Protein and the V Domain of RAGE Using Tranilast.
    Chiou JW; Fu B; Chou RH; Yu C
    PLoS One; 2016; 11(9):e0162000. PubMed ID: 27598566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity.
    Dowarha D; Chou RH; Yu C
    PLoS One; 2020; 15(6):e0234152. PubMed ID: 32497081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical characterization of Ca
    Kim I; Lee KO; Yun YJ; Jeong JY; Kim EH; Cheong H; Ryu KS; Kim NK; Suh JY
    Biochem Biophys Res Commun; 2017 Jan; 483(1):332-338. PubMed ID: 28017722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for the interaction between stress-inducible phosphoprotein 1 (STIP1) and S100A1.
    Maciejewski A; Prado VF; Prado MAM; Choy WY
    Biochem J; 2017 May; 474(11):1853-1866. PubMed ID: 28408431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of the S100A6 mutant (C3S) with the V domain of the receptor for advanced glycation end products (RAGE).
    Mohan SK; Gupta AA; Yu C
    Biochem Biophys Res Commun; 2013 May; 434(2):328-33. PubMed ID: 23537648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentamidine inhibit S100A4 - p53 interaction and decreases cell proliferation activity.
    Katte RH; Chou RH; Yu C
    Arch Biochem Biophys; 2020 Sep; 691():108442. PubMed ID: 32649952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrophobic residues in the C-terminal region of S100A1 are essential for target protein binding but not for dimerization.
    Osterloh D; Ivanenkov VV; Gerke V
    Cell Calcium; 1998 Aug; 24(2):137-51. PubMed ID: 9803314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional solution structure of the calcium-signaling protein apo-S100A1 as determined by NMR.
    Rustandi RR; Baldisseri DM; Inman KG; Nizner P; Hamilton SM; Landar A; Landar A; Zimmer DB; Weber DJ
    Biochemistry; 2002 Jan; 41(3):788-96. PubMed ID: 11790100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100P Interacts with p53 while Pentamidine Inhibits This Interaction.
    Katte RH; Dowarha D; Chou RH; Yu C
    Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33923162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.
    Okada M; Tokumitsu H; Kubota Y; Kobayashi R
    Biochem Biophys Res Commun; 2002 Apr; 292(4):1023-30. PubMed ID: 11944917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of Zn
    Baksheeva VE; Roman AY; Villard C; Devred F; Byrne D; Yatoui D; Zalevsky AO; Vologzhannikova AA; Sokolov AS; Permyakov SE; Golovin AV; Shaw GS; Tsvetkov PO; Zernii EY
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.